SCGL Director/PDMR Shareholding – May 2019

  13 May 2019 Shore Capital Group Limited (“Shore Capital” or the “Company”) Director/PDMR Shareholding Shore Capital was notified today […]

 

Howard Shore Speaks at the Milken Institute Global Conference 2019

Howard Shore, Executive Chairman of Shore Capital Group, discusses Brexit with an esteemed panel at the Milken Institute Global Conference […]

 

SCGL Director/PDMR Dealing

  Shore Capital Group Limited (“Shore Capital” or the “Group”) Director/PDMR Dealing Shore Capital, the independent investment group specialising in […]

 

News |

Shore Capital Markets appointed as Joint Broker to Arbuthnot Banking Group PLC

Shore Capital Markets is delighted to have been appointed as Joint Broker to Arbuthnot Banking Group PLC. Through its principal […]

 

News |

Shore Capital Markets acted as Lead Manager in the Placing & Open Offer for Sirius Minerals Plc

  Shore Capital Markets acted as Lead Manager in the Placing & Open Offer for Sirius Minerals Plc which, together […]

 

News |

Shore Capital acts as Sole Bookrunner on the placing for Arbuthnot Banking Group

Shore Capital is delighted to have acted as sole bookrunner for Arbuthnot Banking Group  PLC (“Arbuthnot”), on a secondary placing […]

 

News |

Shore Capital appointed as Joint Broker to AFH Financial Group PLC

    Shore Capital is delighted to have been appointed as Joint Broker to AFH Financial Group Plc, a leading […]

 

News |

Shore Capital Markets welcomes Stockdale Securities Limited following acquisition

  Shore Capital, the independent investment group, is pleased to announce that its Capital Markets Division, Shore Capital Markets Limited, […]

 

News |

Shore Capital Group Limited – Completion of acquisition

1 April 2019  Shore Capital is pleased to announce that, further to its statement on 13 February in relation to […]

 

Address the solution to the Irish border at the outset of negotiations

  Howard Shore writes in a letter to the editor: The Irish government confirmed this week that the backstop is […]

 

News |

Shore Capital Group Limited Preliminary Results for the Year Ended 31 December 2018

  Shore Capital Group Limited (“Shore Capital”, the “Group”, or the “Company”) Preliminary Results for the Year Ended 31 December […]

 

Update on Holding in Spectrum Investments

  Shore Capital Group Limited (“Shore Capital” or the “Company”) Update on Holding in Spectrum Investments   Shore Capital holds […]

 

News |

Preliminary Results for the Year Ended 31 December 2018

  Shore Capital Group Limited (“Shore Capital”, the “Group”, or the “Company”) Preliminary Results for the Year Ended 31 December […]

 

News |

Update on acquisition of Stockdale Securities

18 March 2019  Shore Capital is pleased to announce that, further to its statement on 13 February in relation to […]

 

News |

M&S and Ocado announce new Joint Venture, Shore Capital acting as Lead Manager and Joint Corporate Broker to M&S

      Marks and Spencer Group Plc (“M&S”) announces the creation of a new 50/50 Joint Venture (“JV”) with […]

 

News |

Non-Standard Finance plc announces £1.3bn all-share offer for Provident Financial plc

Non-Standard Finance plc announced £1.3bn all-share offer for Provident Financial plc. The full Regulatory News Service (RNS) announcement is available […]

 

News |

Shore Capital acting as Joint Broker to Dairy Crest on the Recommended Cash Offer

  Shore Capital is pleased to announce that it is acting as Joint Broker to Dairy Crest in the recommended […]

 

News |

Shore Capital is delighted to have been appointed as Joint Broker to CML Microsystems Plc

      CML Microsystems Plc Appointment of Joint Broker   CML Microsystems Plc, which designs, manufactures and markets semiconductor […]

 

News |

Shore Capital is pleased to announce the acquisition of Stockdale Securities Limited

    Shore Capital Group Limited (“Shore Capital” or the “Company”) Acquisition of Stockdale Securities Limited   Shore Capital, the […]

 

News |

Life Science Analysis: Caution prevails in 2019

Tara Raveendran, Healthcare Analyst at Shore Capital, looks back at 2018’s impressive biotech IPO market and how the tides turned […]

 

Our website uses necessary cookies in order for it to run. We would also like to use optional analytics cookies to improve the site, by collecting and reporting information on how you use it. These cookies do not directly identify the user and won’t set optional cookies unless they are accepted. For more information on how our site cookies work, please see our Privacy Policy.